{"id":543876,"date":"2021-05-19T22:36:02","date_gmt":"2021-05-19T22:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543876"},"modified":"2021-05-19T22:36:02","modified_gmt":"2021-05-19T22:36:02","slug":"lipodystrophy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-regeneron-pharmaceuticals-ionis-pharmaceuticals-pfizer-amunix-zydus-cadila-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lipodystrophy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-regeneron-pharmaceuticals-ionis-pharmaceuticals-pfizer-amunix-zydus-cadila-and-many-others_543876.html","title":{"rendered":"Lipodystrophy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621306841.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lipodystrophy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621306841.jpeg\" alt=\"Lipodystrophy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Lipodystrophy Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy<\/strong> refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at birth (congenital). There are five types of lipodystrophy: Congenital generalized lipodystrophy, acquired generalized lipodystrophy, Acquired partial lipodystrophy, High active antiretroviral therapy-induced lipodystrophy, and Localized lipodystrophy. The specific symptoms present, severity, and prognosis can vary greatly depending upon the specific type of lipodystrophy and the presence and extent of associated symptoms.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Lipodystrophy Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>10+ companies and 10+ pipeline drugs<\/strong> in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Lipodystrophy Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Ionis Pharmaceuticals<\/li>\n<li>Pfizer<\/li>\n<li>Amunix<\/li>\n<li>Zydus Cadila<\/li>\n<li>Galmed Pharmaceuticals<\/li>\n<li>CellPraxis<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Lipodystrophy report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Lipodystrophy Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>REGN4461<\/li>\n<li>Volanesorsen<\/li>\n<li>AMX 342<\/li>\n<li>Vupanorsen<\/li>\n<li>Saroglitazar<\/li>\n<li>CT-SCUP<\/li>\n<li>Aramchol<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Lipodystrophy Treatment Scenario and Lipodystrophy Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Lipodystrophy drugs?<\/li>\n<li>How many Lipodystrophy drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lipodystrophy?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Lipodystrophy therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Lipodystrophy and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Volanesorsen: Ionis Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Vupanorsen: Pfizer<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical stage products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">AMX 342: Amunix<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy Key Companies<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy Key Products<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy Analyst Views<\/p>\n<p style=\"text-align: justify;\">Lipodystrophy Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lipodystrophy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-regeneron-pharmaceuticals-ionis-pharmaceuticals-pfizer-amunix-zydus-cadila-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lipodystrophy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-regeneron-pharmaceuticals-ionis-pharmaceuticals-pfizer-amunix-zydus-cadila-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipodystrophy Pipeline Lipodystrophy refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lipodystrophy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-regeneron-pharmaceuticals-ionis-pharmaceuticals-pfizer-amunix-zydus-cadila-and-many-others_543876.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-543876","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543876"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}